

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on 20 Oct 2008

PATENT
Attorney Docket No.: 015280-405100US
Client Ref. No.: DHHS No.: E-293-1999/0-US-06
Customer No.: 45115

TOWNSEND and TOWNSEND and CREW LLP

By: Malinda Adgett

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LEPPLA *et al.*

Application No.: 10/088,952

Filed: March 22, 2002

For: MUTATED ANTHRAX TOXIN
PROTECTIVE ANTIGEN PROTEINS
THAT SPECIFICALLY TARGET
CELLS CONTAINING HIGH
AMOUNTS OF CELL-SURFACE
METALLOPROTEINASES OR
PLASMINOGEN ACTIVATOR
RECEPTORS

Confirmation No. 4741

Examiner: Fetterolf, Brandon J.

Art Unit: 1642

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT AFTER ALLOWANCE

UNDER 37 CFR § 1.312

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Examiner's telephone request to furnish a Sequence Listing, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification as follows.

Amendments to the Specification begin on page 2 of this paper.

Remarks begin on page 3 of this paper.